The outcomes of patients with metastatic/inoperable gastrointestinal stromal tumors (GIST) treated with imatinib - An interim multicenter analysis of Polish Clinical GIST Registry

Nowotwory

Volumn 55, Issue 3, 2005, Pages 195-199

  Ruka, Włodzimierz ^a   Rutkowski, Potr ^a   Nowecki, Zbigniew ^a   Osuch, Czesław ^b   Starosławska, Elzbieta ^c   Rozmiarek, Andrzej ^d   Krawczyk, Marek ^e   Nyckowski, Paweł ^e   Błasińska Morawiec, Maria ^f   Jagiełło Gruszfeld, Agnieszka ^g   Góźdź, Stanisław ^h   Nasierowska Guttmejer, Anna ^a   Grzesiakowska, Urszula ^a   Utracka Hutka, Beata ⁱ   Michej, Wanda ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c Centrum Onkologii Ziemi Lubelskiej   (Poland)

^d Oncology Center   (Poland)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

^f Department of Oncology   (Poland)

^g Cancer Center ^*  (Poland)

^h Cancer Center   (Poland)

ⁱ INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Clinical outcome; Gastrointestinal stromal tumor; Imatinib

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASCITES; CANCER CENTER; CANCER REGISTRY; CLINICAL TRIAL; DEMOGRAPHY; DIARRHEA; EDEMA; FEMALE; FLUID RETENTION; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INOPERABLE CANCER; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; MITOSIS RATE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; POLAND; RASH; SEX RATIO; SOFT TISSUE INFECTION; SURVIVAL RATE; TUMOR BLEEDING; TUMOR LOCALIZATION; TUMOR REGRESSION; TUMOR VOLUME;

EID: 21244431585     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-34.
2. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-funetion mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
3. Fletcher CDM, Herman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33: 459-65.
4. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. NEJM 2002; 347: 472-80.
5. van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors; a phase I study. Lancet 2001; 358: 1421-23
6. van Oosterom, Judson IR, Verwiej J et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38, Suppl 5: S83-S87.
7. Manley PW, Cowan-Jacob SW, Buchdunger E i wsp. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 2002; 38, Suppl 5: S19-S27.
8. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002; 38, Suppl. 5: S39-S51.
9. DeMatteo RP, Lewis JJ, Leung D et al. Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8.
10. Ruka W, Rutkowski P, Szawłowski A et al. Współczesne postȩpowanie u chorych na miȩsaki podścieliskowe przewodu pokarmowego (GIST - gastrointestinal stromal tumors). Nowotwory J Oncol 2003; 53: 537-42.
11. Schipper JP, Liem RSL, van der Ingh HF et al. Revision of gastrointestinal mesenchymal tumors with CD117. Eur J Surg Oncol 2004; 30: 959-62.
12. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 3813-25.